Early asset strategy informing clinical development

Early asset strategy informing clinical development

Goal

A global top 10 pharma company, wanted to understand potential future market scenarios for an asset in early Phase 1 clinical development. There was a need to identify key areas of unmet need from all stakeholders’ perspectives and to decide on implications for clinical development and TPP (Target Product Profile) definition.

Approach

Analysis

Analyze disease, standard of care, unmet needs and competitor landscape

Patient journey

Define treatment pathway and patient journey

Stakeholder needs

Map needs of all other relevant stakeholders, review TPP and define implications for clinical development

  • Strategic multi-stakeholder insights for early asset strategy informing clinical development for a molecule in clinical development
  • Defined 3 commercialization scenarios and implications for development
  • Consensus to change direction of development to better align with stakeholder needs

Contact our experts

Meike Wenzel

Meike Wenzel

Partner

mail_icon linkedin_icon
Philippe Coune

Philippe Coune

Partner

mail_icon linkedin_icon
Clifford Hall

Clifford Hall

Subject Matter Expert

mail_icon

Learn more about our focus topic

Early Asset Strategy

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.

OK